TauRx

TauRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments and diagnostics for Alzheimer's disease and related neurodegenerative disorders.

Its pipeline centres on tau aggregation inhibitors, which target the pathological accumulation of tau protein implicated in dementia.

The company's lead compound, hydromethylthionine mesylate, has progressed through Phase 3 trials and is the subject of a UK Marketing Authorisation Application submitted to the MHRA.